In patient-derived midbrain neurons we propose to investigate whether N-acetyl-glucosamine (GlcNAc) supplementation can serve as a novel approach to enhance N-linked protein glycosylation which in turn will improve enzyme trafficking, ALP function, and reduce a-syn (Fig 1).Such an approach would be of high interest, since GlcNAc is already available as a dietary supplement and there is little concern about its potential side effects. If GlcNAc supplementation rescues PD models, we can move these studies into α-syn mouse models and ultimately in the clinics.
|Effective start/end date||1/1/19 → 9/30/20|
- Northwestern Memorial Hospital (Awrd 2/22/2019)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.